Breast Cancer PSMA PET

Recruiting now · Early Phase 1

Conditions studied: Triple Negative Breast Cancer

In brief

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.

Key facts

Study ID

NCT06586047

Run by

Ahmad Shariftabrizi

People needed

30

Starts

2024-08-29

Expected to finish

2027-09-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older, up to 90. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female >= 18 years of age
• Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
• Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.

You may not qualify if…

• Patients with known active other malignancy.
• Unable to tolerate PET/CT procedure.
• Pregnant or breastfeeding.
• Patients with any medical condition that might compromise the safety of subject during PET acquisitions.

Where it is running

• University of Iowa Healthcare — Iowa City, Iowa, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.